Haemonetics Corporation (HAE) exhibits 59.0% gross margins and 8.4% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 32.5x enterprise multiple and 6.9% implied options volatility.
Sustained 59.0% gross profitability converts into 11.7% operating margin and 8.4% ROIC, outpacing sector cost of capital.
ROIC: 8.4% // GM: 59.0%YoY revenue trajectory of -2.0% paired with 4.78% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -2.0% // FCF YLD: 4.78%Altman Z-Score of 3.89 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.89 // F-SCORE: 7/9Trading at 185.0x trailing P/E (140.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 185.0x // EV/EBITDA: 32.5xOptions market prices a ±6.9% implied move with a 0.78 put/call ratio around $117.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.78Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 0.0% net margins.
NET MARGIN: 0.0% // D/E: 1.01x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for HAE & activate live FRED threshold breach alerts.